Rational Design of Biobetters with Enhanced Stability

Journal of Pharmaceutical Sciences

Volumn 104, Issue 8, 2015, Pages 2433-2440

  Courtois, Fabienne ^a   Schneider, Curtiss P ^a   Agrawal, Neeraj J ^a   Trout, Bernhardt L ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

biobetter; drug design; molecular modeling; monoclonal antibody; mutation; protein aggregation; rituximab; SAP; stabilization

Indexed keywords

BIOBETTER; BIOLOGICAL PRODUCT; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOLOGICAL THERAPY; DRUG DESIGN; DRUG STABILITY; HYDROPHOBICITY; NONHUMAN; PROTEIN DEGRADATION; SIMULATION; SURFACE PROPERTY; AMINO ACID SUBSTITUTION; ANIMAL; ANTIBODY AFFINITY; B LYMPHOCYTE; BURKITT LYMPHOMA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PROTEIN ENGINEERING; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL LINE, TUMOR; DRUG DESIGN; DRUG STABILITY; EPITOPES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; PROTEIN AGGREGATES; PROTEIN ENGINEERING; PROTEIN STABILITY; RECOMBINANT PROTEINS; RITUXIMAB;

EID: 84947036849     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24520     Document Type: Article

References (31)

1. Aggarwal RS,. 2014. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 32: 32-39.
2. Rader RA. Biosimilars/biobetters pipeline database-Top level data, http://www.biosimilarspipeline.com/. October 30, 2014.
3. Beck A,. 2011. Biosimilar, biobetter and next generation therapeutic antibodies. mAbs 3: 107-110.
4. Rosenberg AS,. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8: 501-507.
5. Kumar S, Singh SK, Wang X, Rup B, Gill D,. 2011. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B cell immune epitopes may contain aggregation prone regions. Pharm Res 28: 949-961.
6. den Engelsman J, Garidel P, Smulders R, et Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W,. 2001. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28: 920-933.
7. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry-Immunogenicity Assessment for Therapeutic Protein Products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf. October 30, 2014.
8. Chennamsetty N, Voyonov V, Kayser V, Helk B, Trout BL,. 2009. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 106: 11937-11942.
9. Chennamsetty N, Helk B, Voyonov V, Kayser V, Trout BL,. 2009. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 391: 404-413.
10. Voynov V, Chennamsetty N, Kayser V, Helk B, Trout BL,. 2009. Predictive tools for stabilization of therapeutic proteins. mAbs 1: 580-581.
11. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr., Bearden JD 3rd, Greco FA,. 2000. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95: 3052-3056.
12. Okamoto H, Kamatani N,. 2004. Rituximab for rheumatoid arthritis. N Engl J Med 351: 1909.
13. Taylor PC,. 2007. Rituximab in the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 3: 17-26.
14. Andersen CB, Manno M, Rischel C, Thõrõlfsson M, Martorana V,. 2010. Aggregation of a multidomain protein: A coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci 19: 279-290.
15. Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, Huo S, Guo Y, Ding J,. 2007. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem 282: 15073-15080.
16. Humphrey W, Dalke A, Schulten K,. 1996. VMD: Visual molecular dynamics. J Mol Graph 14: 33-38.
17. Ye J, Ma N, Madden TL, Ostell JM,. 2013. IgBLAST: An immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res 41: 34-40.
18. Anderson DR, Hanna N, Leonard GE, Newman RA, Reff ME, Rastetter WH,. 1998. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Patent US 5736137.
19. Lee CC, Perchiacca JM, Peter M, Tessier PM,. 2013. Toward aggregation-resistant antibodies by design. Trends Biotechnol 31: 612-620.
20. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL,. 2011. Prediction of protein binding regions. Proteins 79: 888-897.
21. Olsson MHM, Sondergard CR, Rostkowski M, Jensen JH,. 2011. Consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput 7: 525-537.
22. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D,. 2012. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci USA 109: 10879-10884.
23. Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall'Acqua W, Minter R, Jermutus L, Bedian V,. 2013. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression mAbs 5: 255-262.
24. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL,. 2010. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B 114: 6614-6624.
25. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM,. 2004. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10: 2868-2878.
26. Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, Vásquez M, Tessier PM, Xu Y,. 2014. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. mAbs 6: 483-492.
27. Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL,. 2011. Aggregation in protein-based biotherapeutics: Computational studies and tools to identify aggregation prone regions. J Pharm Sci 100: 5081-5095.
28. Wang X, Das TK, Singh SK, Kumar S,. 2009. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. mAbs 1: 254-267.
29. Lauer T, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL,. 2012. Developability index: A rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101: 102-115.
30. Trout BL, Schneider CP, Agrawal NJ,. 2013. Her2-and vegf-a-binding proteins with enhanced stability. Patent US WO2014052713 A3.
31. Trout BL, Schneider CP, Agrawal NJ,. 2013. Cd20-and egfr-binding proteins enhanced stability. Patent US WO2014052717 A3.